期刊
THORAX
卷 70, 期 4, 页码 376-378出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2013-204114
关键词
-
资金
- Astra Zeneca
- GlaxoSmithKline
- Novartis
- Medimmune
- HSC RD (NI)
- GlaxoSmithKline (PhD studentship)
- Wellcome Senior Clinical Fellowship
- National Institute for Health Research [NF-SI-0512-10018] Funding Source: researchfish
Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were 2912 pound (SD 2212) pound to mu 4217 (SD 2449) pound. Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据